A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity

Breast Cancer Research and Treatment

Volumn 153, Issue 1, 2015, Pages 123-133

  Yao, Xuejing ^a   Jiang, Jing ^b   Wang, Xin ^a   Huang, Changjiang ^c   Li, Dong ^a   Xie, Kuan ^a   Xu, Qiaoyu ^c   Li, Hongwen ^a   Li, Zhuanglin ^c   Lou, Liguang ^d   Fang, Jianmin ^a,e,f  

^a TONGJI UNIVERSITY   (China)

^b BINZHOU MEDICAL UNIVERSITY   (China)

^c RemeGen   (China)

^d SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^e SOOCHOW UNIVERSITY   (China)

^f SICHUAN UNIVERSITY   (China)

Author keywords

Antibody therapy; Antibody drug conjugates; HER2; MMAE; Tumor models

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERTUZUMAB; HERTUZUMAB MONOMETHYLAURISTATIN F; HERTUZUMAB VALINE CITRULLINE MONOMETHYLAURISTATIN E; HERTUZUMAB VALINE CITRULLINE MONOMETHYLAURISTATIN F; LAPATINIB; MONOCLONAL ANTIBODY; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; OLIGOPEPTIDE; VEDOTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER RESISTANCE; CONJUGATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; BREAST NEOPLASMS; CHEMICAL STRUCTURE; CHEMISTRY; CYTOTOXICITY; DISEASE MODEL; DRUG RESISTANCE; DRUG SCREENING; IMMUNOLOGY; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY AFFINITY; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOCONJUGATES; MOLECULAR STRUCTURE; OLIGOPEPTIDES; RECEPTOR, ERBB-2; TRASTUZUMAB; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84939255871     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3503-3     Document Type: Article

References (34)

1. Slamon DJ, Clark GM, Wong SG et al (1994) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182
2. Paik S, Burkhard E, Lippman ME (1992) Clinical significance of erbB2 protein overexpression. Cancer Treat Res 61:181–191
3. Ross JS, Slodkowska EA, Symmans WF et al (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:320–368
4. Arteaga CL, Sliwkowski MX, Osborne CK et al (2012) Treatment of HER2- positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 9:16–32
5. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med 344:783–792
6. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684
7. Dua R, Zhang J, Nhonthachit P et al (2010) EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance. Breast Cancer Res Treat 122:685–697
8. Di CS, Serpico D, Porcu L et al (2014) Clinical outcome of HER2-positive breast cancer patients after failure on adjuvant trastuzumab: the potential of the time to relapse. Clin Oncol (R Coll Radiol) 26:174
9. Janthur WD, Cantoni N, Mamot C (2012) Drug conjugates such as antibody drug conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice. Int J Mol Sci 13:16020–16045
10. Lambert JM (2013) Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol 76:248–262
11. King HD, Dubowchik GM, Mastalerz H et al (2002) Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethylene glycol chains. J Med Chem 45:4336–4343
12. Thudium K, Bilic S, Leipold D et al (2013) American association of pharmaceutical scientists national biotechnology conference short course: translational challenges in developing antibody-drug conjugates. Mabs 5:5–12
13. Ricart AD (2011) Antibody-drug conjugates of calicheamicin derivative: gemtuzumabozogamicin and inotuzumabozogamicin. Clin Cancer Res 17:6417–6427
14. Katz J, Janik JE, Younes A (2011) BrentuximabVedotin (SGN-35). Clin Cancer Res 17:6428–6436
15. LoRusso P, Weiss D, Guardino E et al (2011) Trastuzumabemtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 17:6437–6447
16. Verma S, Miles D, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791
17. Lewis Phillips GD, Li G, Dugger DL et al (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280–9290
18. Doronina SO, Toki BE, Torgov MY et al (2003) Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 21:778–784
19. Pettit GR (1997) The dolastatins. Fortschr Chem Org Naturst 70:1–79
20. Zhang DP, Wu ZY, Li XY et al (2002) Purification and identification of a 42-kilodalton abscisic acid-specific-binding protein from epidermis of broad bean leaves. Plant Physiol 128:714–725
21. Higashihara M, Frado LLY, Craig R et al (1989) Inhibition of conformational change in smooth muscle myosin by a monoclonal antibody against the 17 kD light chain. J Biol Chem 264:5218–5225
22. Norderhaug L, Olafsen T, Michaelsen TE et al (1997) Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells. J Immunol Methods 204:77–87
23. Hamblett KJ, Senter PD, Chace DF et al (2004) Effects of drug loading on antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 10:7063–7070
24. O’Brien NA, Browne BC, Chow L et al (2010) Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9:1489–1502
25. Lewis GD, Figari I, Fendly B et al (1993) Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 37:255–263
26. Dubowchik GM, Firestone RA (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg Med Chem Lett 8:3341–3346
27. Dubowchik GM, Firestone RA (1998) Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), mitomycin C and doxorubicin. Bioorg Med Chem Lett 8:3347–3352
28. Ribrag V, Dupuis J, Tilly H et al (2014) A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 20:213–220
29. Hamann PR, Hinman LM, Hollander I et al (2002) Gemtuzumabozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 13:47–58
30. DiJoseph JF, Armellino DC, Boghaert ER et al (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood 103:1807–1814
31. Doronina SO, Mendelsohn BA, Bovee TD et al (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114–124
32. Doronina SO, Bovee TD, Meyer DW et al (2008) Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 19:1960–1963
33. Oflazoglu E, Stone IJ, Gordon K et al (2008) Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 14:6171–6180
34. Sun MM, Beam KS, Cerveny CG et al (2005) Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 16:1282–1290